Pulmonary metastatic melanoma is cancer that originated in melanocytes-pigment-producing cells-and has spread from its primary site to the lungs. This condition typically arises in advanced-stage melanoma, often classified as stage 4 disease, and indicates systemic involvement beyond the skin or original tumor location.
Metastasis to the lungs is common in melanoma due to the organ's rich blood supply and high capillary density. Once melanoma cells enter the bloodstream, they can lodge in pulmonary tissue and grow into secondary tumors. The presence of lung metastases affects survival and treatment planning.
According to the American Cancer Society, approximately 15% to 20% of patients with cutaneous melanoma develop distant metastases, with the lungs being the most frequent site. These metastases may appear months or years after initial diagnosis, even after successful treatment of the primary tumor.
Metastatic melanoma reaches the lungs through hematogenous spread-meaning cancer cells travel via the bloodstream. Melanoma cells can survive in circulation, adhere to lung capillaries, and invade alveolar tissue. They then proliferate, forming nodules visible on imaging.
Detection usually begins with routine follow-up scans after initial melanoma treatment. Chest CT scans are standard for identifying pulmonary lesions. A single nodule or multiple nodules-often 5 mm to several centimeters in size-may appear. PET scans help distinguish active tumor tissue from scar tissue or benign nodules.
For example, a 52-year-old woman with a history of stage III melanoma treated with surgery and immunotherapy underwent a surveillance CT scan six months post-treatment. The scan revealed two 1.2 cm nodules in the right lower lobe. Biopsy confirmed metastatic melanoma, not a new primary lung cancer. This case illustrates how asymptomatic metastasis can be detected early through screening.
Pulmonary metastatic melanoma is not categorized by type but by stage and burden. The AJCC (American Joint Committee on Cancer) staging system classifies melanoma based on tumor thickness, ulceration, lymph node involvement, and distant metastasis. When melanoma spreads to the lungs, it is designated as M1c, the most aggressive form of distant spread.
| Stage | Definition | Lung Involvement? |
|---|---|---|
| M1a | Metastasis to skin, subcutaneous tissue, or lymph nodes | No |
| M1b | Metastasis to lung parenchyma or other organs without elevated LDH | Yes |
| M1c | Metastasis to any site with elevated serum lactate dehydrogenase (LDH) | Yes |
LDH levels above normal indicate higher tumor burden and poorer prognosis. Elevated LDH is seen in about 30% of patients with pulmonary metastatic melanoma and correlates with reduced median survival.
A non-obvious distinction: pulmonary metastases from melanoma are often indistinguishable from primary lung cancers on imaging. Radiologists rely on clinical history, lesion appearance (e.g., irregular borders, pleural tags), and biopsy results to confirm origin. Misdiagnosis as primary lung adenocarcinoma is rare but possible, especially in smokers with no known melanoma history.
Many patients with pulmonary metastatic melanoma remain asymptomatic until the disease progresses. When symptoms occur, they include chronic cough (60% of symptomatic cases), shortness of breath (45%), chest pain (30%), and hemoptysis (coughing up blood, 15%). Fatigue and unintentional weight loss are also reported.
Some assume that lung symptoms in melanoma patients always signal recurrence. However, pulmonary complications can stem from other causes-such as infection, radiation pneumonitis, or drug-induced lung injury from immunotherapy. For instance, pembrolizumab, a PD-1 inhibitor used in advanced melanoma, can cause immune-related pneumonitis, mimicking tumor progression on CT scans.
One patient I monitored had persistent cough and new lung nodules on follow-up CT. Initial concern was metastatic melanoma. But a bronchoscopy with biopsy showed inflammation and granulomas-indicating drug-induced pneumonitis. Steroids resolved the issue. This case underscores the need for histologic confirmation before assuming malignancy.
Treatment depends on disease burden, performance status, and molecular markers. Systemic therapies include targeted therapy (for BRAF-mutant melanoma), immunotherapy (anti-PD-1 agents), and combination regimens. Surgery is considered only in select cases with limited, isolated lung metastases.
For example, a 48-year-old man with BRAF V600E-positive melanoma developed two lung nodules after completing adjuvant dabrafenib/trametinib. He underwent surgical resection of both nodules. Post-op, he resumed targeted therapy and remained disease-free for 24 months. This outcome supports the role of metastasectomy in highly selected patients.
Prognosis remains poor. Median survival for patients with pulmonary metastatic melanoma is 12 to 18 months. However, those responding to immunotherapy have longer survival-some live beyond five years. Response rates to anti-PD-1 drugs like nivolumab are around 30% in metastatic disease, with durable responses in a subset.
Survival varies by treatment modality:
It's critical to understand that pulmonary metastatic melanoma is not a single entity. Its behavior differs based on genetic profile, immune microenvironment, and patient-specific factors. Not all metastases progress rapidly. Some remain stable for extended periods, especially under effective systemic control.
If you've been diagnosed with melanoma and experience new respiratory symptoms-especially after treatment-consult your oncologist promptly. Imaging and biopsy are essential to differentiate between recurrence, infection, or treatment side effects.
Early detection improves outcomes. Surveillance protocols recommend baseline CT scans within six months of treatment completion, followed by annual scans for at least five years. Patients with high-risk features may require more frequent monitoring.